The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
The event also featured discussions on emerging trends in joint replacement surgery
Routine regulatory filing confirms completion of demat and share transfer compliances for March quarter
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
The last-mile healthcare delivery across 1,100 villages, with focus on maternal health, diagnostics, and chronic disease management
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
Subscribe To Our Newsletter & Stay Updated
